Companies
GlycanAge
London-headquartered GlycanAge, spun out of Croatian glycoscience research, markets a biological-age test based on immunoglobulin G (IgG) glycosylation rather than DNA methylation; a May 2026 study run jointly with Circulate Health analyzed roughly 20,000 individuals across 42 studies,…
- Country
- United Kingdom
glycan-clock
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | €7.4 million (US$8.7 million) in December 2025 led by Fifth Quarter Ventures | agetechworld.co.uk · en.lider.media · parsers.vc · eu-startups.com |
| Funding | Over €40 million in grant funding secured for research and development | glycanage.com · parsers.vc |
| Headcount | Over 30 to 45 employees | en.lider.media · parsers.vc |
| Revenue | $6.2 million in next twelve months (NTM) revenue medium confidence | impetus.capital |
| Regulatory approval | Utilizes CLIA-certified laboratory pathways for LDTs in the US and is progressing through IVDR frameworks in Europe | parsers.vc |
| Production site | Primary research and development laboratory in Croatia; additional laboratory in California, USA; planned laboratory in Saudi Arabia (KACST) | agetechworld.co.uk · en.lider.media · parsers.vc · eu-startups.com |
Independent sources: agetechworld.co.uk · en.lider.media · eu-startups.com · impetus.capital · parsers.vc
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Epigenetic clocks & biological-age diagnostics | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.